Neurocrine Biosciences Inc. (NASDAQ:NBIX), a biopharmaceutical company focused on developing treatments for neurological and endocrine-related diseases, has been navigating a complex landscape of ...

Despite finishing strong across both its innovative and generic businesses in 2024, Teva’s cautious approach to the new year ...

Teva Pharmaceutical Industries Limited’s TEVA share price has dipped by 13.89%, which has investors questioning if this is ...

We assign Teva a Morningstar Uncertainty Rating of High, which largely reflects our quantitative analysis of the firm, based on the return ranges used by our star rating system, as well as our ...

Operator Hello, and welcome to the fourth quarter and full year 2024 Teva Pharmaceutical Industries earnings conference call.

Usually described as a splitting or multiple personality disorder, the concept of schizophrenia is not entirely but rather a ...

HB Wealth Management LLC bought a new stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) during the ...

Wedbush reduced their FY2024 earnings per share estimates for shares of Neurocrine Biosciences in a report released on ...

It is also used to treat tardive dyskinesia, another form of movement disorder. Sales were $638 million last year and according to Teva will approach the $1 billion mark in 2021, despite the ...

Women tend to respond more favorably to SSRIs than to tricyclics, have more side effects with psychotropic medication, and are more likely to develop tardive dyskinesia. They may also be more ...

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that Andrew Ratz, Ph.D., has joined the company as Senior Vice ...

The elderly are more susceptible to pneumonia than younger populations. The prevalence of both disability and comorbid diseases increase with age and are associated with increased risk of pneumonia.